Influenza Virus Vaccine

Presented by: Mahak Ajmera

Contents

Company Introduction

Health Care Portfolio

Influenza Virus

Products

Vaccine Development Process

GSK - Influenza Virus Vaccine 12/3/2014 2

GlaxoSmithKline

World largest research based pharmaceutical corporation that discover, develops, manufactures and markets branded health care products.

GSK - Influenza Virus Vaccine 12/3/2014 3

2012

Source:http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Annual-Report-2012.pdf

Key Facts

GSK - Influenza Virus Vaccine 12/3/2014 4

GlaxoSmithKline - Mission

GSK - Influenza Virus Vaccine 12/3/2014 5

GlaxoSmithKline - Where they are?

GSK - Influenza Virus Vaccine 12/3/2014 6

GSK - Turnover

GSK - Influenza Virus Vaccine 12/3/2014 7

Source:http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Annual-Report-2012.pdf

Healthcare Portfolio

Pharmaceuticals

Infectious diseases

Cancer

Epilepsy

Heart Disease

Asthma and chronic pulmonary disease

AIDS

GSK - Influenza Virus Vaccine 12/3/2014 8

Vaccines

Hepatitis A and B

Diphtheria, Tetanus, Whooping cough

Polio

Measles, Mumps, Rubella

Typhoid

Influenza

Bacterial meningitis

Consumer

Healthcare

Oral Care

Nutritional

Total wellness

Skin Health

Healthcare Portfolio

GSK - Influenza Virus Vaccine 12/3/2014 9

Source:http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Annual-Report-2012.pdf

GlaxoSmithKline Vaccines – Market Share

GSK - Influenza Virrus Vaccine 12/3/2014 10

Source: http://who.int/influenza_vaccines_plan/resources/session_10_kaddar.pdf

Influenza

Influenza (the flu) contagious respiratory disease caused by influenza viruses.

Affect the respiratory track (nose, throat and lungs).

Symptoms : fever, headache, malaise, cough, sore throat, nasal congestion and body aches.

10% to 20% of the population is infected with influenza virus each year

It can cause to severe illness and at times lead to death.GSK - Influenza Virus Vaccine 12/3/2014 11

Types of Influenza Virus

GSK - Influenza Virus Vaccine 12/3/2014 12

Sr. No

Basis Type A Type B Type C

1 Symptoms Moderate to Severe Mild Mild

2 Age Group All Primarily children All

3 Affect Humans and animal Affects human only

Affects human only

4 Divided Subdivided based on antigenic differences

Not divided intosub types

Not divided into sub types

5 Epidemics Widespread Regional Don’t cause

6 Experienced Mostly Less Common than type A

RarelyReported

Influenza A Virus

Is subdivide into two distinct large surface glycoprotein's antigens.

H- Haemagglutinin which initiates infection and attachment of virus to the susceptible cell

N- Neuraminidase which is responsible for release of virus from the infected cell

Mutations in the antigenic structure of the influenza virus have resulted in a number of different influenza subtypes and strains (antigenic drift)

H Type (1-15) and N Type (1-9)

Only H1, H2 and H3 and N1, N2 are found in humans.

Example: H1N1,H2N2,H3N2 etc.

GSK - Influenza Virrus Vaccine 12/3/2014 13

Source: Karl G Nicholson, John M Wood, Maria Zambon, THE LANCET • Vol 362 • November 22, 2003 • www.thelancet.com

Influenza Virus

GSK - Influenza Virus Vaccine 12/3/2014 14

Source: http://en.wikipedia.org/wiki/File:InfluenzaNomenclatureDiagram.svg

Influenza Outbreak

GSK - Influenza Virus Vaccine 12/3/2014 15

Types of Influenza Vaccines

Inactivated Vaccine (Killed)

• These type of vaccine are produced by killing the virus with chemicals, heat or radiation.

• There are three types of inactivated vaccine whole virus, split virus and subunit vaccine.

• They are generally injected (intramuscular).

Live Attenuated Vaccine

• The vaccine contain a version of weakened strain of virus.

• They are given intranasal.

GSK - Influenza Virus Vaccine 12/3/2014 16

Fluarix

Suspension for injection supplied in 0.5-mL single-dose prefilled syringes

Composition:

• A/Christchurch/16/2010 (H1N1)

• A/Texas/50/2012 (H3N2)

• B/Massachusetts/2/2012

GSK - Influenza Virus Vaccine 12/3/2014 17

Source: https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1244169218783&featureKey=600572

Fluarix Quadrivalent

GSK - Influenza Virus Vaccine 12/3/2014 18

Suspension for injection supplied in 0.5-mL single-dose prefilled syringes

Composition:

• A/Christchurch/16/2010 (H1N1)

• A/Texas/50/2012 (H3N2)

• B/Brisbane/3/2007

• B/Brisbane/60/2008

Source: https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1358783243411&featureKey=603902

FluLaval

GSK - Influenza Virus Vaccine 12/3/2014 19

Supplied in a 5-mL multi-dose vial containing 10 doses (0.5-mL each)

Composition:

• A/California/7/2009 (H1N1)

• A/Texas/50/2012 (H3N2)

• B/Massachusetts/2/2012

Source: https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1244169337831&featureKey=600581

FluLaval Quadrivalent

GSK - Influenza Virus Vaccine 12/3/2014 20

Supplied in a 5-mL multi-dose vial containing 10 doses (0.5 mL each)

Composition:

• A/California/7/2009 (H1N1)

• A/Texas/50/2012 (H3N2)

• B/Massachusetts/2/2012

• B/Brisbane/60/2008

Source:https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1378227924542&featureKey=604242

Pandemrix

GSK - Influenza Virus Vaccine 12/3/2014 21

For influenza pandemic (H1N1) also know as swine flu

Supplied as suspension to be mixed with emulsion adjuvant (AS03) before injection

Composition:

• A/California/7/2009 (H1N1)

GSK Flu Vaccine Development Process

GSK - Influenza Virus Vaccine 12/3/2014 22

Source: http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Flu-Vaccine-Production-Process.pdf

GSK Flu Vaccine Development Process

GSK - Influenza Virus Vaccine 12/3/2014 23

GSK Flu Vaccine Development Process

GSK - Influenza Virus Vaccine 12/3/2014 24

GSK Flu Vaccine Development Process

GSK - Influenza Virus Vaccine 12/3/2014 25

GSK - Influenza Virus Vaccine 12/3/2014 26

References

http://www.gsk.com/about-us/what-we-do.html

http://www.gsk.com/products/our-vaccines.html

https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductsByName#F

http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Annual-Report-2012.pdf

http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Flu-Vaccine-Production-Process.pdf

GSK - Influenza Virus Vaccine 12/3/2014 27